S

South Texas Accelerated Research Therapeutics | START Madrid - CIOCC

Research site

(Unclaimed)

Location

Calle Oña 10,  Planta 3 Hospital Universitario HM Sanchinarro, Madrid, Madrid, Spain

Site insights

Top conditions

Top treatments

BOS172738

Futibatinib

Temozolomide

Fulvestrant

Tinostamustine

Parent organization

This site is a part of South Texas Accelerated Research Therapeutics

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 4 total trials

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of Debio 0123 combined with tem...

Enrolling

Astrocytoma, Grade III

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Drug: Debio 0123

Drug: Temozolomide

A Study of TAS-120 in Patients With Metastatic Breast Cancer

The purpose of the trial is to evaluate a patient's response to a Fibroblast Growth Factor Receptor (FGFR) inhibitor, futibatinib (TAS-120), used eit...

Active, not recruiting

FGFR 1 High Amplification

FGFR2 Amplification

Drug: Futibatinib

Drug: Futibatinib plus Fulvestrant

Study of Tinostamustine for Adjuvant Treatment of Glioblastoma

The study is designed as an open label, multi-center, Phase 1 study of single agent tinostamustine, used as adjuvant treatment in patients with newly...

Active, not recruiting

Glioblastoma Multiforme

Drug: Tinostamustine

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms